Want to see IN:EMCURE full AI Analyst Report?
Emcure Pharmaceuticals Limited (EMCURE) Ratios
Emcure Pharmaceuticals Limited Ratios
IN:EMCURE's free cash flow for Q4 2024 was $3.80B. For the 2024 fiscal year, IN:EMCURE's free cash flow was decreased by $-1.12B and operating cash flow was $4.91B. See a summary of the company’s cash flow.
| Ratios | Mar 25 | Mar 25 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 1.71 | 1.43 |
| Quick Ratio | 0.98 | 0.82 |
| Cash Ratio | 0.05 | 0.03 |
| Solvency Ratio | 0.30 | 0.29 |
| Operating Cash Flow Ratio | 0.32 | 0.22 |
| Short-Term Operating Cash Flow Coverage | 1.57 | 0.89 |
| Net Current Asset Value | $ 9.65B | $ 9.76B |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.12 | 0.16 |
| Debt-to-Equity Ratio | 0.23 | 0.31 |
| Debt-to-Capital Ratio | 0.19 | 0.24 |
| Long-Term Debt-to-Capital Ratio | 0.04 | 0.05 |
| Financial Leverage Ratio | 1.85 | 1.94 |
| Debt Service Coverage Ratio | 2.19 | 1.37 |
| Interest Coverage Ratio | 7.75 | 9.56 |
| Debt to Market Cap | 0.04 | 0.04 |
| Interest Debt Per Share | 62.17 | 87.84 |
| Net Debt to EBITDA | 0.60 | 0.75 |
| Profitability Margins | ||
| Gross Profit Margin | 0.35% | 38.89% |
| EBIT Margin | 14.23% | 15.55% |
| EBITDA Margin | 19.15% | 20.06% |
| Operating Profit Margin | 13.89% | 14.92% |
| Pretax Profit Margin | 12.44% | 13.99% |
| Net Profit Margin | 8.73% | 10.04% |
| Continuous Operations Profit Margin | 9.06% | 10.23% |
| Net Income Per EBT | 70.14% | 71.81% |
| EBT Per EBIT | 89.55% | 93.71% |
| Return on Assets (ROA) | 8.28% | 9.62% |
| Return on Equity (ROE) | 15.32% | 18.67% |
| Return on Capital Employed (ROCE) | 19.49% | 24.10% |
| Return on Invested Capital (ROIC) | 17.61% | 14.98% |
| Return on Tangible Assets | 9.35% | 10.86% |
| Earnings Yield | 3.39% | 3.06% |
| Efficiency Ratios | ||
| Receivables Turnover | 3.80 | 3.59 |
| Payables Turnover | 0.04 | 3.11 |
| Inventory Turnover | 0.03 | 2.35 |
| Fixed Asset Turnover | 3.19 | 3.69 |
| Asset Turnover | 0.95 | 0.96 |
| Working Capital Turnover Ratio | 0.00 | 5.13 |
| Cash Conversion Cycle | 2678.92 | 139.93 |
| Days of Sales Outstanding | 96.08 | 101.63 |
| Days of Inventory Outstanding | 11033.21 | 155.61 |
| Days of Payables Outstanding | 8450.37 | 117.32 |
| Operating Cycle | 11129.29 | 257.25 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | 45.54 | 44.87 |
| Free Cash Flow Per Share | 23.78 | 25.85 |
| Dividend Paid and CapEx Coverage Ratio | 2.09 | 2.04 |
| Capital Expenditure Coverage Ratio | 2.09 | 2.36 |
| Operating Cash Flow Coverage Ratio | 0.83 | 0.56 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.09 |
| Free Cash Flow Yield | 2.21% | 1.62% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | 2502.44 | 32.72 |
| Price-to-Sales (P/S) Ratio | 2.58 | 3.29 |
| Price-to-Book (P/B) Ratio | 4.53 | 6.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 45.25 | 61.74 |
| Price-to-Operating Cash Flow Ratio | 23.63 | 35.56 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 |
| Enterprise Value Multiple | 14.06 | 17.14 |
| Enterprise Value | 210.27B | 316.33B |
| EV to EBITDA | 14.06 | 17.14 |
| EV to Sales | 2.69 | 3.44 |
| EV to Free Cash Flow | 47.28 | 64.56 |
| EV to Operating Cash Flow | 24.69 | 37.19 |
| Tangible Book Value Per Share | 197.53 | 204.48 |
| Shareholders’ Equity Per Share | 237.71 | 261.17 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.27 |
| Revenue Per Share | 417.46 | 485.59 |
| Net Income Per Share | 36.43 | 48.77 |
| Tax Burden | 0.70 | 0.72 |
| Interest Burden | 0.87 | 0.90 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.11 | 0.24 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | 0.88 | 0.92 |
Currency in INR
